Drug Approval | May 07, 2024
Alembic Pharmaceuticals receives EIR from USFDA for oncology formulation facility
With this, for all our USFDA facilities, EIRs are in place
With this, for all our USFDA facilities, EIRs are in place
Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
The company has posted net loss of Rs. 105.07 crores for the Financial Year ended March 31, 2024
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
The company has reported total income of Rs. 155.79 crores during the period ended March 31, 2024
The company has posted net profit of Rs.87.66 crores for the Financial Year ended March 31, 2024
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
Colchicine Capsules are indicated for prophylaxis of gout flares in adult
Subscribe To Our Newsletter & Stay Updated
